Cash and cash equivalents amounted to $69.8M as of September 30, compared to $32.5M as of December 31, 2024, a net increase of $37.4M. The company said, “The increase in Research tax credit during the three and the nine months ended September 30, 2025, is primarily due to the fact that more eligible activities have been carried out in the period, including the related costs of the FAREVA platform.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- DBV Technologies S.A. – American Depositary Shares (DBVT) Q3 Earnings Cheat Sheet
- Optimistic Outlook for DBV Technologies Amid Promising Viaskin Peanut Advancements
- DBV Technologies to sell $30M of ADSs through at-the-market program
- DBV Technologies Announces Board Member Resignation
- DBV Technologies Launches $150M ATM Equity Offering